Guide
Metabolic dysfunction-associated steatohepatitis (MASH) is an advanced form of non-alcohoic fatty liver disease, and it very well could be the silent reason your costs are spiking.
7 Reasons Employers and Health Plans Need to Get Ahead of MASH Costs
MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.
Resources
-
7 Reasons Employers and Health Plans Need to Get Ahead of MASH Costs
MASH isn’t a new problem, it’s a newly visible one. As obesity and diabetes continue to drive healthcare costs, metabolic liver disease is emerging as a critical missing piece in many employer strategies.
-
Expanding access to obesity care: Breaking the cost barrier through innovative benefit design
Watch the on-demand webinar that takes a deep dive into how organizations can respond to GLP-1 demand even when the medications aren’t covered on their formulary.
-
What you need to know in the new GLP-1 landscape
Watch the on-demand webinar that takes a deep dive into how new pricing for GLP-1s is reshaping access and raising questions about how to design sustainable benefits.